Related Experiment Video
Updated: Jul 26, 2025
08:05
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
14.2K
CROI 2023: Acute and Post-Acute COVID-19
Annukka A R Antar1, Michael J Peluso2
1Johns Hopkins University, Baltimore, Maryland, USA.
Topics in Antiviral Medicine
|June 14, 2023
Summary
Early treatment with ensitrelvir for COVID-19 accelerated viral clearance and symptom recovery, potentially reducing long COVID. Research also explores new SARS-CoV-2 treatments and long COVID therapies.
Area of Science:
- Infectious Diseases
- Virology
- Immunology
Background:
- The 2023 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted recent advancements in understanding and treating COVID-19.
- Acute and post-acute sequelae of SARS-CoV-2 infection, including long COVID, remain significant global health concerns.
- Co-infection of HIV and SARS-CoV-2 presents unique challenges and research opportunities.
Purpose of the Study:
- To summarize key findings from the 2023 CROI meeting concerning COVID-19 and related research.
- To highlight novel therapeutic strategies for acute COVID-19 and long COVID.
- To present new insights into SARS-CoV-2 infection in individuals with HIV.
Main Methods:
- Review of presentations and studies from the 2023 CROI conference.
- Analysis of data on antiviral treatments, therapeutic targets for long COVID, and co-infection studies.
- Synthesis of information on emerging agents with broad sarbecovirus activity.
Main Results:
- Ensitrelvir, a protease inhibitor, demonstrated efficacy in hastening viral clearance and symptom resolution in acute COVID-19.
- Ensitrelvir treatment also appeared to reduce the incidence of long COVID symptoms.
- Development of novel agents, including anti-ACE2 monoclonal antibodies, targeting SARS-CoV-2 and broader sarbecoviruses is progressing.
- Understanding of long COVID pathophysiology is advancing, identifying potential therapeutic targets.
- Studies on COVID-19 in people with HIV have yielded insights into SARS-CoV-2 coinfection biology.
Conclusions:
- Novel antiviral agents and therapeutic strategies show promise for managing acute COVID-19 and its long-term effects.
- Further research into long COVID pathophysiology is crucial for developing effective treatments.
- Understanding SARS-CoV-2 in vulnerable populations like those with HIV is essential for comprehensive disease management.
More Related Videos
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
2.8K
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
750
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
153
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
153
01:21Acute Respiratory Failure-I
253
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
253
01:30Acute Respiratory Failure-III
234
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
234
01:21Acute Respiratory Failure-II
287
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
287
01:30Acute Pharyngitis
972
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
972
01:29Acute Respiratory Failure-V
169
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
169